Vasomune Therapeutics has appointed Douglas A. Hamilton as president and chief executive officer of the company. Mr. Hamilton will also be appointed to Vasomune’s Board of Directors.    “I am delighted to be joining Vasomune and its team of founders, dedicated scientists, consultants and high-profile institutional investors,” said Mr. Hamilton.  “By selectively targeting the host response, Vasomune’s therapeutic approach focuses on a single, non-redundant pathway that inhibits multiple factors...